Business Context and Reporting Period
Company: Protagonist Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 26, 2018
Context: The Company is an emerging growth company developing investigational oral GI-restricted alpha-4-beta-7 integrin antagonist peptides. This filing reports a significant clinical development event regarding its lead candidate, PTG-100.
Key Financial Metrics
This Form 8-K filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on a specific corporate event.
Material Changes and Events
- Discontinuation of Phase 2b PROPEL Study: The Company announced the discontinuation of the Phase 2b PROPEL study of PTG-100 in patients with moderate to severe ulcerative colitis.
- Reason for Discontinuation: An independent Data Monitoring Committee (DMC) conducted a planned interim analysis of unblinded efficacy and safety data from the first 65 patients (out of 240) who completed 12 weeks of treatment.
- DMC Conclusion: Based on pre-specified criteria, the DMC deemed the trial futile regarding the primary endpoint of clinical remission.
- Safety Profile: No safety concerns were noted in the interim analysis.
- Impact on Other Programs: The decision to initiate a Phase 2/3 clinical trial of PTG-100 in chronic pouchitis has been postponed pending a full review of the interim data from the discontinued study.
Guidance, Outlook, and Risks
Outlook: The Company has paused the timeline for the chronic pouchitis trial until the full review of the ulcerative colitis interim data is complete. No specific financial guidance or future revenue projections were provided in this filing.
Risks: The filing highlights the risk of clinical trial failure and the potential impact on the development timeline of the Company's lead asset, PTG-100.
Key Facts for Investor Verification
- Verify the specific pre-specified criteria used by the DMC to determine futility.
- Confirm the timeline for the "full review" of interim data and the subsequent decision on the chronic pouchitis trial.
- Assess the impact of this discontinuation on the Company's cash runway and future capital requirements, as this information is not included in the 8-K.
- Review the Company's pipeline to determine if other assets are affected by the alpha-4-beta-7 integrin antagonist data.